Browsing Centre for Immunobiology by Author "Wahl, J"
Now showing items 1-3 of 3
-
C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks
Foster, GR; Agarwal, K; Cramp, M; Moreea, S; Barclay, ST; Collier, J; Brown, AS; Ryder, SD; Ustianowski, A; Forton, DM (2016-10) -
Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study
Hezode, C; Fried, MW; Colombo, M; Bourliere, M; Spengler, U; Ben-Ari, Z; Strasser, SI; Perumalswami, P; Zamor, P; Lee, WM (2016-12-02) -
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Foster, GR; Agarwal, K; Cramp, ME; Moreea, S; Barclay, S; Collier, J; Brown, AS; Ryder, SD; Ustianowski, A; Forton, DM (2018-06)Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis. The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) ...